"U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration's approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly's oral drug, orforglipron, is still under review. Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness."
"The Novo Nordisk obesity pill contains 25 milligrams of semaglutide. That's the same ingredient in injectables Wegovy and Ozempic and in Rybelsus, a lower-dose pill approved to treat diabetes in 2019. In a clinical trial, participants who took oral Wegovy lost 13.6% of their total body weight on average over about 15 months, compared with a 2.2% loss if they took a placebo, or dummy pill. That's nearly the same as injectable Wegovy, with an average weight loss of about 15%."
FDA approved a daily oral Wegovy pill containing 25 mg semaglutide as the first daily oral medication for obesity, giving Novo Nordisk an edge over Eli Lilly whose oral candidate remains under review. Both oral drugs are GLP-1 agonists that mimic a hormone controlling appetite and fullness. Clinical trial participants taking oral Wegovy lost about 13.6% of body weight over roughly 15 months versus 2.2% with placebo, close to injectable Wegovy's average 15% loss. Oral availability is expected within weeks and could broaden access, lower costs, and reach patients who cannot afford or prefer not to use injectables.
Read at www.bostonherald.com
Unable to calculate read time
Collection
[
|
...
]